-
Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
Wednesday, November 2, 2016 - 12:05pm | 341Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...